Frontlight ResearchEarly access
CompletedPhase 3
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Key facts
- Who runs it
- argenx
- Where
- Columbus, Iowa City, Ocala, and Washington D.C., United StatesSee the 4 sitesAlso in 17 other countries, 68 sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 101 people enrolled
- Started
- 2 Jun 2020
- Ended
- 11 Mar 2026
- Type of study
- Interventional
- Treatments tested
- efgartigimod
- Record updated
- 16 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits)
- Patients enrolled in the ARGX-113-1801 trial who completed the 24-weeks trial period
- Women of childbearing potential must have a negative urine pregnancy test at baseline before trial medication (infusion) can be administered
- Women of childbearing potential should use a highly effective or acceptable method of contraception during the trial and for 90 days after the last administration of the IMP. They must be on a stable regimen, for at least 1 month (as listed in the protocol)
- Ability to understand the requirements of the additional 52-week treatment period of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits)
- Patient has completed a 52-week treatment period
Who cannot take part
- Introduction or continuation of non-permitted medications during the ARGX-113-1801 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins or live/live-attenuated vaccines)
- Use of any other investigational drug or participation in any other investigational trial
- Patients with known medical history of hypersensitivity to any of the ingredients of efgartigimod
- Pregnant or lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing
Where in United States
Also in 17 other countries, 68 sites
- Columbus, OhioHospital not named in the registry
- Iowa City, IowaHospital not named in the registry
- Ocala, FloridaHospital not named in the registry
- Washington D.C., District of ColumbiaHospital not named in the registry
About the trial
What the trial wants to find out
This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.
The group in the trial
- efgartigimodTreatment being tested
patients receiving efgartigimod
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia.
- Record updated
- 16 March 2026